ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The double inhibition of BCR-ABL and PKCδ decreased the clonogenic capacity of CML CD34+ cells by 90% using IMA (Figure 5B) or DASA, NILO, BOSU, and PONA (Figure S13), again with homogeneous responses.